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ScienceDirectOver the last decade we have witnessed the convergence of
two powerful experimental designs toward a common goal of
defining the molecular subtypes that underpin the likelihood of
a cancer patient responding to treatment in the clinic. The first
of these ‘experiments’ has been the systematic sequencing of
large numbers of cancer genomes through the International
Cancer Genome Consortium and The Cancer Genome Atlas.
This endeavour is beginning to yield a complete catalogue of
the cancer genes that are critical for tumourigenesis and
amongst which we will find tomorrow’s biomarkers and drug
targets. The second ‘experiment’ has been the use of large-
scale biological models such as cancer cell lines to correlate
mutations in cancer genes with drug sensitivity, such that one
could begin to develop rationale clinical trials to begin to test
these hypotheses. It is at this intersection of cancer genome
sequencing and biological models that there exists the
opportunity to completely transform how we stratify cancer
patients in the clinic for treatment.
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Introduction
All cancers arise due to the acquisition of somatic
mutations in their genomes, which fundamentally alter
the function of the protein products of key cancer genes
[1]. Such mutations are responsible not only for the
development of the cancer in the first instance but also
for maintaining the proliferation status and evasion of cell
death that are the hallmarks of cancer [2]. To date
approximately 500 genes have been identified for which
Open access under CC BY license.Current Opinion in Genetics & Development 2014, 24:114–119 mutations (including somatic coding changes and struc-
tural rearrangements) have been causally implicated in
cancer (http://www.sanger.ac.uk/genetics/CGP/Census/)
[3]. Moreover, next-generation sequencing of large num-
bers of tumours across many tissue types is currently
underway as part of the International Cancer Genome
Consortium (ICGC) and The Cancer Genome Atlas
(TCGA), and we can expect to have within a decade
complete catalogues of somatic mutations for many of
the most prevalent cancer types (www.icgc.org; http://
cancergenome.nih.gov/).
There is an expectation that these studies will reveal
genetic dependencies in cancer that can be targeted
therapeutically to improve patient survival. Indeed they
have begun to reveal pathways and cellular processes that
are subverted in cancer and that may be promising drug
targets. However, it is also clear that cross-talk between
such pathways and compensatory  signalling following
drug treatment are also present and as such can only
be captured by the examination of how cancer cells
respond to treatment over time. Such ‘dynamic’ exper-
iments by their nature require biological models, and
here we discuss how large-scale cancer cell line models
can be used to associate mutated pathways and processes
with the likelihood of drug response in cancer patients.
Cancer genomics and drug response in the
clinic
While most of the current treatment regimens for cancer
are based on the tissue of origin, the clinical response of
cancer patients to treatment with a particular drug is often
highly variable. There is a compelling body of evidence,
both clinical and experimental, that for an increasing
number of drugs used in the clinic the likelihood of a
patient’s cancer responding to treatment is strongly influ-
enced by alterations in the cancer genome (Table 1) [4–
14]. Critically, these genomic changes can be used as
molecular biomarkers to identify patients most likely to
benefit from a particular treatment. Arguably the most
celebrated example of this has been the use of imatinib, a
small molecule inhibitor of the ABL1 tyrosine kinase, to
target the fusion protein product of the BCR-ABL trans-
location seen in chronic myeloid leukaemia [15]. More
recently, the use of EGFR and ALK inhibitors in lung
cancer patients whose tumours harbour EGFR mutations
and EML4-ALK rearrangements, respectively, as well as
BRAF inhibitors in melanoma has resulted in significantly
improved response rates compared to conventional thera-
pies in those subsets of patients [5,6,9]. Equally strikingwww.sciencedirect.com
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Table 1
FDA-approved targeted cancer drugs in clinical use that are dependent for activity on the presence of a genomic alteration in the
patient’s tumour. Approved small molecule inhibitors and antibodies targeting specific drug-sensitizing mutations in human cancers.
Although these mutations dramatically affect the likelihood of a given patient responding to a particular therapy, it is pertinent to note that
in many cases these mutations are only present in a subset of that specific tumour type. Identification of these subgroups using next-
generation sequencing technologies will become increasingly important for the management of cancer patients in the clinic
Tumour Gene
(mutation)
Prevalence
of gene
alteration (%)
FDA-
approved
drug
Year
approved
Therapeutic
target
Response rate
in mutant
tumours (%)
Study
Chronic myeloid
leukaemia
BCR-ABL
(translocation)
>95 Imatinib 2001 ABL1 >95 Druker et al. [4]
Gastrointestinal
stromal tumour
KIT (mutation),
PDGFRA
(mutation)
85 (KIT),
5–8 (PDGFRA)
Imatinib 2002 KIT,
PDGFRA
>80 Verweij et al. [8]
Non-small cell
lung cancer
EGFR (mutation) 10 Gefitinib,
erlotinib
2003,
2004
EGFR 70 Mok et al. [6]
Chronic myeloid
leukaemia
(imatinib-resistant)
BCR-ABL
(translocation)
>95 Dasatanib 2006 ABL1 >90 Talpaz et al. [7]
Breast cancer–
node +ve
HER2 amplification 15–20 Trastuzunab 2006 ERBB2 HR 0.48 Perez et al. [13]
Melanoma BRAF (mutation) 40–70 Vemurafenib 2011 BRAF >50 Chapman et al. [20]
Non-small cell
lung cancer
EML4-ALK
(translocation)
2-7 Crizotinib 2011 ALK 57 Kwak et al. [5]
Melanoma BRAF (mutation) 40–70 Debrafenib 2013 BRAF 52 Hauschild et al. [10]
Melanoma BRAF (mutation) 40–70 Trametinib 2013 MEK1 22 Flaherty et al. [11]
Non-small cell
lung cancer
EGFR (mutation) 10 Afatinib 2013 EGFR/ERBB2 50 Yang et al. [12]
Breast cancer
(metastatic)
HER2 amplification 15–20 Trastuzumab 2013 ERBB2 44 Verma et al. [14]
Abbreviations: KIT, v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homologue; PDGFRA, platelet-derived growth factor receptor; alpha
polypeptide.has been the rapid development of targeted therapies
compared to the timeline for cytotoxic therapies, best
exemplified by the development of ALK inhibitors for
lung cancer, which took less than 5 years from initial
identification of the EML4-ALK rearrangement as a
molecular biomarker to clinical approval of the drug.
Despite the relative success of these approaches, the
number of genomic biomarkers used in the clinic is very
small, and the development of new genomic biomarkers
has the potential to improve the application of the
majority of new and existing therapies. Moreover, even
appropriately selected patient populations exhibit a
poorly explained range of clinical responses, such as
the 60% response rate in BRAF mutated melanoma
patients, which currently limit the effectiveness of even
the most targeted approaches. The emergence of clinical
resistance appears to be almost a universal feature of
targeted therapies, and new clinical strategies incorporat-
ing improved biomarkers will be required to monitor,
counteract and prevent the emergence of drug resistance.
Systematic screens to identify molecular biomarkers to
better guide patient therapies, as well as to counter act
drug resistance, could have a profound impact on the
development of new cancer therapies and ultimately in
improving patient outcomes. Therefore, one can begin to
imagine how a large panel of cancer cell lines that havewww.sciencedirect.com been extensively characterised and assayed for their
sensitivity to a large collection of pre-clinical and clinical
therapeutic agents might enable therapeutic biomarker
discovery (Figure 1).
Cancer cell lines as models for drug
biomarker discovery
Immortalised cancer cell lines serve as highly useful and
tractable experimental models for cancers in patients and,
to a substantial extent, recapitulate in vitro the genetic
and biological complexity of cancer. From the establish-
ment of the HeLa cell line almost 50 years ago, they have
been the mainstay of biological investigation of human
cancer [16]. The current, globally available set of approxi-
mately 1000–1500 experimentally usable cancer cell lines
constitutes an extraordinarily useful resource that is ubi-
quitously used in cancer biology and drug development.
In particular, cancer cell lines have proven to be invalu-
able models for cell intrinsic processes and can be used to
study the effects on many existing targeted cancer thera-
pies.
Nonetheless, there are specific aspects of cancer biology
that are difficult to faithfully model cancer cell lines.
These include the effect of tumour–stroma interaction,
immune surveillance, invasion and metastasis, angiogen-
esis and the role of stem cell populations. Moreover, asCurrent Opinion in Genetics & Development 2014, 24:114–119
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Figure 1
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Pharmcogenomic profiling in cancer cells. The genomics of drug sensitivity in cancer project has assembled a panel of >1000 cancer cell lines
covering a broad range of tissue types and that have been extensively characterised by exome sequencing, copy number analysis, DNA methylation
and mRNA gene expression profiling. Each cell line has drug sensitivity data for a large number of pre-clinical and clinical compounds. These data can
be used to identify combinations of mutations, copy number alterations or transcriptional programs that best explain drug response in cancer
(www.cancerrxgene.org).cell lines can be likened to a snapshot of a tumour, they
are not well suited for the study of cancer initiation or
progression. This can only be studied properly by
employing more complex experimental systems; cell
lines have shown themselves to be robust models of cell
intrinsic processes. A number of recent publications
describing the landscape of driver mutations across a
range of cancers have highlighted the mutational hetero-
geneity present in any given tumour type [17–25]. Sim-
ilarly, gene expression studies of clinical samples have
also defined molecularly defined subgroups within a
number of tumour types [26,27,28]. It is entirely plaus-
ible that these molecularly defined subgroups will exhibit
different biological characteristics including drug
response and therefore any screen that utilises cancer
cell lines must be of sufficient scale to capture both the
tissue-type and genetic diversity of human cancers. Only
in this way will it be possible to accurately model the
effect of cancer mutations on drug response.Current Opinion in Genetics & Development 2014, 24:114–119 Large-scale drug screens in cancer cell lines
One of the first systematic efforts to use cancer cell lines
to identify biomarkers of drug sensitivity was the NCI-60
panel at the National Cancer Institute in 1990 [29]
(http://dtp.nci.nih.gov/branches/btb/ivclsp.html).
Although these 60 cell lines have now been screened
against many thousands of chemical agents, it has become
increasingly clear that much larger numbers of cell lines
are required to capture the genetic diversity of human
cancer. It is now clear from next-generation sequencing
studies that cancers are remarkably heterogeneous and
many cancer genes are present in only a fraction of any
tumour type. It is therefore likely that hundreds of cancer
cell lines would be required to capture this landscape of
cancer gene mutations.
To address this need, a Wellcome Trust Sanger Institute
and Massachusetts General Hospital collaboration was
established in 2009 to screen >1000 cancer cell lineswww.sciencedirect.com
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Table 2
The advantages and disadvantages of using cancer cell lines to model cancer biology. It is pertinent to note that many of the current
disadvantages of established cancer cell lines could be negated through the generation of tumour organoid cancer models using novel
tissue culture and sequencing technologies
Advantages Disadvantages
Cancer is an intrinsic disease
of cells.
Some cancer types are very poorly represented as cancer cell lines, for example prostate cancer.
Cancer cell lines are derived
from naturally occurring human
cancers.
Even for those cancer classes that are represented, there are relatively small numbers available as
cancer cell lines.
Cancer cell line resources capture
at least some of the cell-of–origin
and mutational diversity of cancer.
Cancer cell lines do not reflect the cell-type or tissue architecture of the tissue from which they were
derived.
Cancer cell lines are routinely
used in drug development.
The available set of cancer cell lines have adapted to culture in multiple different ways. They have
been derived over five decades or more in a large number of laboratories under widely differing
conditions, and have been grown for widely differing numbers of passages.
Cancer cell lines are tractable for
high-throughput analysis as
well as gene silencing and
overexpression experiments.
The available set of cancer cell lines appears to represent, for many cancer classes, a subset of cases
with pre-existing favourable intrinsic features that have allowed establishment in in vitro culture.
For most cancer cell lines there is little or no clinical or pathological data attached.
For most cancer cell lines, a normal sample from the same individual is not available and hence we
cannot clearly identify the somatic mutations present in the cell line.
For almost all cancer cell lines, there has not been parallel genomic or other characterisation of the
primary cancer from which it was derived in order to assess the degree of similarity (or difference) and
the extent to which the line has evolved in vitro.
The recent explorations of cancer genomes through sequencing, with concomitant discovery of new
cancer genes, have revealed how patchy is the recapitulation of key driver events in each cancer type
within the current series of cancer cell lines, and how few of the combinations of mutated cancer
genes are found therein.against 400 cancer drugs and to make that data publicly
accessible (pharmacologic profiles of 142 cancer drugs
screened across 668 cell lines are currently available)
(http://www.cancerrxgene.org/) (Figure 1). A similar
initiative funded by the pharmaceutical company Novar-
tis at the Broad Institute has profiled 24 cancer drugs
across 504 cell lines (http://www.broadinstitute.org/ccle/
home). A key element of both endeavours is the detailed
genomic, epigenetic and transcriptomic characterisation
that has been made possible for these cancer cell lines by
advances in next-generation sequencing, such that multi-
dimensional signatures of drug response can be derived
from such screens and that could be used to stratify
patients for clinical trial recruitment or treatment in
the clinic. Landmark papers by both these groups
recently demonstrated the power of these large screens
to identify both novel and previously documented bio-
markers of drug response in a completely unbiased
fashion [18,30]. It is now feasible to consider profiling
all new experimental oncology compounds in such
screens in order to develop hypotheses as to mechanisms
of activity as well as insights into patient subgroups that
may be most likely to respond to treatment in the clinic.
Tumour organoids as the next generation of
cancer cell models
Although the current set of cancer cell lines has demon-
strated value when used at sufficient scale to capture thewww.sciencedirect.com genetic diversity of human cancer, it has a number of
drawbacks (Table 2). Foremost among these has been the
low success rate in deriving these cell lines from patient
biopsies in the past, with the result that some tumour
types are very poorly represented (e.g. prostate cancer)
and the cell lines available do not completely capture the
genetic diversity present in the patient population. It is
possible therefore to envisage the ideal scenario for
derivation of a new panel of cancer cell lines, where
phenotypically stable cells could be generated with high
success rates from patient biopsies together with clinical
data and where matched normal tissue from the same
patient could also be cultured for experimental assays.
Recently the Clevers lab has recently shown that it is
possible to establish long-term cultures from a variety of
adult mouse and human primary tissues and cancers
(‘organoids’), which can be expanded for many months
in vitro without genetic or phenotypic changes [31,32].
The essential ingredients of the Matrigel-based 3D orga-
noid cultures are a combination of specific growth factors
known to exert strong agonistic effects on critical signal-
ling pathways. Currently, organoid cultures can be made
routinely for colon, stomach, and liver [32,33,34]. Proto-
cols for their derivation from pancreas, prostate and lung
cancers are also being developed. These organoid cul-
tures will need to be extensively characterised to deter-
mine their stability over time and to what degree theyCurrent Opinion in Genetics & Development 2014, 24:114–119
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this technology raises the possibility of generating a new
panel of tumour organoid cultures to replace the current
1000 cancer cell lines that are currently available. These
developments are the specific focus of an article in this
edition of Current Opinion in Genetics and Development
(‘Organoid cultures for the analysis of cancer pheno-
types’).
Concluding remarks
Remarkable advances in DNA sequencing technologies
are transforming our ability to define the mutational
burden of any given cancer and in the near future these
data will become a routine part of the clinical decision-
making process to stratify patients for treatment. In order
to empower clinicians to interpret how these mutations
can affect cancer treatment outcome there will be a
continual need for model systems to functionally link
these genomic alterations with drug response. Cancer cell
lines screened at sufficient scale to capture the existing
genetic diversity provide a route into defining the patient
subgroups that are more likely to respond to any given
therapy. Furthermore, many of the current disadvantages
of the current cancer cell lines will potentially be over-
come in the near future by their replacement with poten-
tially even larger panels of tumour organoid models. Thus
it is likely that such systematic efforts to understand the
biology of drug response in cancer will become increas-
ingly important for any new drug in order to better
understand the patient subgroup most likely to respond
in the clinic. Indeed, one can readily imagine a time in the
not too distant future when all new cancer therapeutics
will be routinely submitted to such screens and the
hypotheses generated used to guide clinical trial design.
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